Clinical trial
48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis…
NCT00114361 · Foundation for Liver Research, Other · Completed
Key facts
| NCT number | NCT00114361 |
|---|---|
| Title | 48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection |
| Official title | Peginterferon Alfa-2a and Ribavirin Combination Therapy in Patients With HBeAg-negative Chronic HBV Infection (PARC Study) |
| Lead sponsor | Foundation for Liver Research, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | Ribavirin, Peginterferon alpha 2a |
| Enrollment | 138 |
| Start date | Mar 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Apr 1, 2010 |
| First posted | Jun 15, 2005 |
| Last update posted | Jun 22, 2010 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: